Supernus stock rises 5% following FDA approval of Onapgo for Parkinson's disease
seekingalpha.com — February 4, 2025, 05:00 PM UTC
Supernus Pharmaceuticals' stock increased by 5% after the FDA approved its wearable device, Onapgo, for Parkinson's disease. This device is the first FDA-approved subcutaneous apomorphine infusion for managing motor fluctuations in advanced cases. Onapgo, previously known as SPN-830, will be available in the U.S. starting in the second quarter of 2025. This approval marks a significant development in treatment options for patients with advanced Parkinson's disease.